Nasdaq · CIK 0000886744
GERN GERON CORP
Insider trading from SEC Form 4. Last filing 11 d ago. Close $1.23 on Oct 9, 2026, +15% from the 52-week low and -37% from the high.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
15
with a Form 4 at this company
Price and insider trades, last year
GERNOct 9, 2026 · close 1.23
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
Open-market buys and sells at GERON CORP, scored.
| Score | Insider | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 41Moderate | Bryan Lawlis V director buy | $16k 13,300 shares | - | 0% from low-75% from high | |
| 49Moderate | James Ziegler EVP, Chief Commercial Officer buy | $160k 100,000 shares | - | - | |
| 48Moderate | John A Scarlett Chairman, President and CEO buy | $22k 12,500 shares | - | - | |
| 40Moderate | Scott Alan Samuels EVP, Chief Legal Officer buy | $24k 15,000 shares | +128% | - |
Transactions
The last 34 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | Robert J. Spiegel director | AGrant or award Common Stock | +6,351 | $1.23 | $7,812 | 212,161 | 11 d ago |
| Oct 20, 2025 | Ahmed ElNawawi EVP, Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +3,000,000 | $0.00 | $0 | 3,000,000 | Oct 20, 2025 |
| Sep 30, 2025 | Robert J. Spiegel director | AGrant or award Common Stock | +5,702 | $1.37 | $7,812 | 188,546 | Oct 1, 2025 |
| Aug 7, 2025 | Harout Semerjian President and CEO | AGrant or award Stock Option (right to buy)derivative | +7,000,000 | $0.00 | $0 | 7,000,000 | Aug 8, 2025 |
| Aug 7, 2025 | Harout Semerjian President and CEO | AGrant or award Stock Option (right to buy)derivative | +4,000,000 | $0.00 | $0 | 4,000,000 | Aug 8, 2025 |
| Jun 30, 2025 | Robert J. Spiegel director | AGrant or award Common Stock | +5,540 | $1.41 | $7,811 | 182,844 | Jul 1, 2025 |
| May 21, 2025 | Robert J. Spiegel director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | Bryan Lawlis V director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | John F McDonald director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | Susan Molineaux director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | Elizabeth G. O'Farrell director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | Dawn Carter Bir Interim President and CEO | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 21, 2025 | Gaurav Aggarwal director | AGrant or award Stock Option (right to buy)derivative | +180,000 | $0.00 | $0 | 180,000 | May 22, 2025 |
| May 9, 2025 | Bryan Lawlis V director | POpen-market purchase Common Stock | +13,300 | $1.18 | $16k | 13,300 | May 13, 2025 |
| Mar 29, 2024 | Robert J. Spiegel director | AGrant or award Common Stock | +2,462 | $3.30 | $8,125 | 166,502 | Apr 2, 2025 |
| Sep 30, 2024 | Robert J. Spiegel director | AGrant or award Common Stock | +1,767 | $4.54 | $8,022 | 170,185 | Apr 2, 2025 |
| Dec 31, 2024 | Robert J. Spiegel director | AGrant or award Common Stock | +2,206 | $3.54 | $7,809 | 172,391 | Apr 2, 2025 |
| Mar 31, 2025 | Robert J. Spiegel director | AGrant or award Common Stock | +4,913 | $1.59 | $7,812 | 177,304 | Apr 2, 2025 |
| Jun 28, 2024 | Robert J. Spiegel director | AGrant or award Common Stock | +1,916 | $4.24 | $8,124 | 168,418 | Apr 2, 2025 |
| Feb 27, 2025 | Scott Alan Samuels EVP, Chief Legal Officer | POpen-market purchase Common Stock | +15,000 | $1.61 | $24k | 26,682 | Mar 3, 2025 |
| Feb 27, 2025 | James Ziegler EVP, Chief Commercial Officer | POpen-market purchase Common Stock | +100,000 | $1.60 | $160k | 100,000 | Mar 3, 2025 |
| Feb 27, 2025 | John A Scarlett Chairman, President and CEO | POpen-market purchase Common Stock | +12,500 | $1.77 | $22k | 12,500 | Mar 3, 2025 |
| Feb 18, 2025 | Michelle Robertson EVP, Chief Financial Officer | AGrant or award Stock Option (right to buy)derivative | +656,000 | $0.00 | $0 | 656,000 | Feb 20, 2025 |
| Feb 18, 2025 | Andrew J Grethlein EVP, Chief Operating Officer | AGrant or award Stock Option (right to buy)derivative | +839,000 | $0.00 | $0 | 839,000 | Feb 20, 2025 |
| Feb 18, 2025 | John A Scarlett Chairman, President and CEO | AGrant or award Stock Option (right to buy)derivative | +2,457,000 | $0.00 | $0 | 2,457,000 | Feb 20, 2025 |
| Feb 18, 2025 | Scott Alan Samuels EVP, Chief Legal Officer | AGrant or award Stock Option (right to buy)derivative | +621,000 | $0.00 | $0 | 621,000 | Feb 20, 2025 |
| Feb 18, 2025 | James Ziegler EVP, Chief Commercial Officer | AGrant or award Stock Option (right to buy)derivative | +529,000 | $0.00 | $0 | 529,000 | Feb 20, 2025 |
| Feb 18, 2025 | John A Scarlett Chairman, President and CEO | AGrant or award Restricted Stock Unitsderivative | +410,000 | $0.00 | $0 | 410,000 | Feb 20, 2025 |
| Feb 18, 2025 | Scott Alan Samuels EVP, Chief Legal Officer | AGrant or award Restricted Stock Unitsderivative | +104,000 | $0.00 | $0 | 104,000 | Feb 20, 2025 |
| Feb 18, 2025 | Andrew J Grethlein EVP, Chief Operating Officer | AGrant or award Restricted Stock Unitsderivative | +140,000 | $0.00 | $0 | 140,000 | Feb 20, 2025 |
| Feb 18, 2025 | James Ziegler EVP, Chief Commercial Officer | AGrant or award Restricted Stock Unitsderivative | +89,000 | $0.00 | $0 | 89,000 | Feb 20, 2025 |
| Feb 18, 2025 | Michelle Robertson EVP, Chief Financial Officer | AGrant or award Restricted Stock Unitsderivative | +110,000 | $0.00 | $0 | 110,000 | Feb 20, 2025 |
| Dec 31, 2024 | Robert J. Spiegel director | AGrant or award Common Stock | -2,206 | $0.00 | $0 | 172,391 | Jan 2, 2025 |
| Nov 11, 2024 | Joseph Eid EVP, Research and Development | AGrant or award Stock Option (right to buy)derivative | -2,500,000 | $0.00 | $0 | 2,500,000 | Nov 12, 2024 |
Insiders
Everyone who has filed a Form 4 here.
- Gaurav Aggarwaldirector
- Dawn Carter BirInterim President and CEO
- Joseph EidEVP, Research and Development
- Ahmed ElNawawiEVP, Chief Commercial Officer
- Andrew J GrethleinEVP, Chief Operating Officer
- Bryan Lawlis Vdirector
- John F McDonalddirector
- Susan Molineauxdirector
- Elizabeth G. O'Farrelldirector
- Michelle RobertsonEVP, Chief Financial Officer
- John A ScarlettChairman, President and CEO
- Scott Alan SamuelsEVP, Chief Legal Officer
- Harout SemerjianPresident and CEO
- Robert J. Spiegeldirector
- James ZieglerEVP, Chief Commercial Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.